<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for http://feeds.benzinga.com/benzinga</title><link>http://feeds.benzinga.com/benzinga</link><description>Individual feed output.</description><lastBuildDate>Thu, 21 Aug 2025 15:37:43 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Walmart Stock Falls on Mixed Q2 Results Despite Raised Guidance</title><link>https://www.benzinga.com/trading-ideas/movers/25/08/47267638/walmart-stock-falls-on-mixed-q2-results-despite-raised-guidance</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/21/Walmart_6.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Walmart Inc. (NYSE: WMT) shares are trading lower Thursday after the company posted mixed second-quarter results. read more</description><pubDate>Thu, 21 Aug 2025 19:25:47 GMT</pubDate></item><item><title>Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder</title><link>https://www.benzinga.com/news/fda/25/08/47267611/ionis-pharma-wins-fda-nod-for-first-rna-targeted-therapy-for-rare-genetic-swelling-disorder</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/21/Woman--Scientist--MedicalResearch.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. read more</description><pubDate>Thu, 21 Aug 2025 19:24:53 GMT</pubDate></item><item><title>Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years</title><link>https://www.benzinga.com/analyst-stock-ratings/initiation/25/08/47267244/achieve-life-sciences-inches-closer-to-fda-nod-for-first-new-quit-smoking-drug-i</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/21/Number-Of-Cigarettes-Isolated-Tobacco-Da.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation ma...</description><pubDate>Thu, 21 Aug 2025 19:11:26 GMT</pubDate></item><item><title>Nvidia's Earnings Could Make Or Break Momentum ETFs</title><link>https://www.benzinga.com/etfs/specialty-etfs/25/08/47266981/nvidias-earnings-could-make-or-break-momentum-etfs</link><image_url>https://cdn.benzinga.com/files/images/story/2025/08/21/NVIDIA-Corporation.jpeg?optimize=medium&amp;dpr=1&amp;auto=webp&amp;height=675&amp;width=1200&amp;fit=crop</image_url><description>Goldman Sachs traders predict a reversal for momentum stocks, putting pressure on ETFs linked to factors ahead of Nvidia's earnings next week. read mo...</description><pubDate>Thu, 21 Aug 2025 19:03:36 GMT</pubDate></item><item><title>SharkNinja Options Trading: A Deep Dive into Market Sentiment</title><link>https://www.benzinga.com/insights/options/25/08/47266914/sharkninja-options-trading-a-deep-dive-into-market-sentiment</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>read more</description><pubDate>Thu, 21 Aug 2025 19:01:56 GMT</pubDate></item></channel></rss>